176 related articles for article (PubMed ID: 15704211)
1. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.
Saft C; Zange J; Andrich J; Müller K; Lindenberg K; Landwehrmeyer B; Vorgerd M; Kraus PH; Przuntek H; Schöls L
Mov Disord; 2005 Jun; 20(6):674-9. PubMed ID: 15704211
[TBL] [Abstract][Full Text] [Related]
2. Clinical correlates of mitochondrial function in Huntington's disease muscle.
Turner C; Cooper JM; Schapira AH
Mov Disord; 2007 Sep; 22(12):1715-21. PubMed ID: 17557337
[TBL] [Abstract][Full Text] [Related]
3. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy.
Lodi R; Schapira AH; Manners D; Styles P; Wood NW; Taylor DJ; Warner TT
Ann Neurol; 2000 Jul; 48(1):72-6. PubMed ID: 10894218
[TBL] [Abstract][Full Text] [Related]
4. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism.
Seong IS; Ivanova E; Lee JM; Choo YS; Fossale E; Anderson M; Gusella JF; Laramie JM; Myers RH; Lesort M; MacDonald ME
Hum Mol Genet; 2005 Oct; 14(19):2871-80. PubMed ID: 16115812
[TBL] [Abstract][Full Text] [Related]
5. [From gene to disease; HD gene and Huntington disease].
Maat-Kievit JA; Losekoot M; Roos RA
Ned Tijdschr Geneeskd; 2001 Nov; 145(44):2120-3. PubMed ID: 11723754
[TBL] [Abstract][Full Text] [Related]
6. Prefrontal executive function associated coupling relates to Huntington's disease stage.
Unschuld PG; Liu X; Shanahan M; Margolis RL; Bassett SS; Brandt J; Schretlen DJ; Redgrave GW; Hua J; Hock C; Reading SA; van Zijl PC; Pekar JJ; Ross CA
Cortex; 2013; 49(10):2661-73. PubMed ID: 23906595
[TBL] [Abstract][Full Text] [Related]
7. Systemic energy homeostasis in Huntington's disease patients.
Aziz NA; Pijl H; Frölich M; Snel M; Streefland TC; Roelfsema F; Roos RA
J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1233-7. PubMed ID: 20710011
[TBL] [Abstract][Full Text] [Related]
8. Neurobiology of Huntington's Disease.
De Souza RA; Leavitt BR
Curr Top Behav Neurosci; 2015; 22():81-100. PubMed ID: 25205327
[TBL] [Abstract][Full Text] [Related]
9. [Huntington disease. A review].
Bonilla E
Invest Clin; 2000 Jun; 41(2):117-41. PubMed ID: 10961047
[TBL] [Abstract][Full Text] [Related]
10. Autopsy-proven Huntington's disease with 29 trinucleotide repeats.
Kenney C; Powell S; Jankovic J
Mov Disord; 2007 Jan; 22(1):127-30. PubMed ID: 17115386
[TBL] [Abstract][Full Text] [Related]
11. Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects.
Ciammola A; Sassone J; Alberti L; Meola G; Mancinelli E; Russo MA; Squitieri F; Silani V
Cell Death Differ; 2006 Dec; 13(12):2068-78. PubMed ID: 16729030
[TBL] [Abstract][Full Text] [Related]
12. Juvenile onset Huntington's disease--clinical and research perspectives.
Nance MA; Myers RH
Ment Retard Dev Disabil Res Rev; 2001; 7(3):153-7. PubMed ID: 11553930
[TBL] [Abstract][Full Text] [Related]
13. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study.
Lemiere J; Decruyenaere M; Evers-Kiebooms G; Vandenbussche E; Dom R
J Neurol; 2004 Aug; 251(8):935-42. PubMed ID: 15316797
[TBL] [Abstract][Full Text] [Related]
14. Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease?
Squitieri F; Frati L; Ciarmiello A; Lastoria S; Quarrell O
Mech Ageing Dev; 2006 Feb; 127(2):208-12. PubMed ID: 16274727
[TBL] [Abstract][Full Text] [Related]
15. Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice.
Oláh J; Klivényi P; Gardián G; Vécsei L; Orosz F; Kovacs GG; Westerhoff HV; Ovádi J
FEBS J; 2008 Oct; 275(19):4740-55. PubMed ID: 18721135
[TBL] [Abstract][Full Text] [Related]
16. Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease.
Hoffmann R; Stüwe SH; Goetze O; Banasch M; Klotz P; Lukas C; Tegenthoff M; Beste C; Orth M; Saft C
Mov Disord; 2014 May; 29(6):831-4. PubMed ID: 24710776
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice.
Oliveira JM; Jekabsons MB; Chen S; Lin A; Rego AC; Gonçalves J; Ellerby LM; Nicholls DG
J Neurochem; 2007 Apr; 101(1):241-9. PubMed ID: 17394466
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of copper ion mediated Huntington's disease progression.
Fox JH; Kama JA; Lieberman G; Chopra R; Dorsey K; Chopra V; Volitakis I; Cherny RA; Bush AI; Hersch S
PLoS One; 2007 Mar; 2(3):e334. PubMed ID: 17396163
[TBL] [Abstract][Full Text] [Related]
19. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release.
Choo YS; Johnson GV; MacDonald M; Detloff PJ; Lesort M
Hum Mol Genet; 2004 Jul; 13(14):1407-20. PubMed ID: 15163634
[TBL] [Abstract][Full Text] [Related]
20. Metabolism in HD: still a relevant mechanism?
Duan W; Jiang M; Jin J
Mov Disord; 2014 Sep; 29(11):1366-74. PubMed ID: 25124273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
